Company profile
Stereotaxis, Inc.
AMEX: STXS · Healthcare · Medical - Equipment & Services
#490 of 1,418 Healthcare companies by revenue67th-percentile growth
EA Score
55CFH 48DQ 57GM 64SS 70
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ filing timeliness, return on equity
Methodology →Revenue TTM
$31.2M
Rev growth YoY (TTM)
+13.4%
Net income (FY)
-$21.6M
Employees
131
as of 2026-08-14
Market cap
$135.1M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$32.4M$32.4M2025
Net income-$21.6M-$21.6M2025
Operating income-$22.1M-$22.1M2025
Total assets$52.3M$52.3M2025
Liabilities$33.5M$33.5M2025
Equity$13.5M$13.5M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Disposables Service and Accessories68%
Systems32%
By geography
Non-US60%
UNITED STATES40%
The read
What is Stereotaxis, Inc.’s revenue?
Stereotaxis, Inc. booked $32.4M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -66.8% net margin.
Peers · Healthcare
Arcus Biosciences, Inc.47DC21 Investments Inc.49DGrown Rogue International Inc.52DAoxing Pharmaceutical Company, Inc.——MediPharm Labs Corp.61CelectroCore, Inc.57CNeighbors
St. Louis (Independent City) →Key facts
CEODavid L. Fischel
SectorHealthcare
IndustryMedical - Equipment & Services
HeadquartersSt. Louis, MO
ExchangeAMEX: STXS
Employees131
IPO date2004-08-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.